Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Risk & Volatility
Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its stock price is 186,326% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Eloxx Pharmaceuticals and LENZ Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 0 | 2 | 2 | 3.00 |
| LENZ Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
Institutional and Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Eloxx Pharmaceuticals and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
Earnings & Valuation
This table compares Eloxx Pharmaceuticals and LENZ Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | 10.16 | -$5.99 million | ($1.54) | -10.39 |
| LENZ Therapeutics | $19.09 million | 6.12 | -$82.13 million | ($4.09) | -0.91 |
Eloxx Pharmaceuticals has higher earnings, but lower revenue than LENZ Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Eloxx Pharmaceuticals beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
